Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of DCR-PH1 in primary hyperoxaluria type 1
NL-OMON44062Phase 1Active, not recruiting
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Aug 2016
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of DCR-PH1 in Primary Hyperoxaluria Type 1 (PH1) (2 arms), sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoint: Safety and tolerability. Started Aug 2016; status: active, not recruiting.
02
Drugs
DCR-PH1
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NL-OMON44062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44062.